DuoGenic StemCells Corporation

As of June 30, 2026, DuoGenic StemCells Corporation carries a market capitalization of 498.48M, placing it among publicly traded companies globally. Its enterprise value stands at 492.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, DuoGenic StemCells Corporation has 36.65M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DuoGenic StemCells Corporation maintains a current ratio of 1.86, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, DuoGenic StemCells Corporation's stock has declined approximately 41.50% over the past 52 weeks. The 50-day moving average sits at 10.39, while the 200-day moving average is 14.43.

As of June 30, 2026, DuoGenic StemCells Corporation holds 32.85M in cash and equivalents against 26.79M in total debt, resulting in a net debt position of -8.39M. Total book value stands at 41.80M, with working capital of 27.10M providing operational flexibility.